Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M
Service de pneumologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-St-Jacques, 75014 Paris, France; Inserm UMRS1138, équipe « cancer, immune control and escape », centre de recherche des Cordeliers, Paris Descartes université, 75006 Paris, France.
GRC n(o) 04, Theranoscan, Sorbonne université, hôpital Tenon, AP-HP, 75020 Paris, France.
Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19.
Lung cancer is the leading cause of cancer deaths in France, with about 30,000 deaths per year. The overwhelming majority (90 %) are tobacco-related. The prognosis is dark but great therapeutic advances have been made with the development of targeted therapies first and then immunotherapy afterwards. These medications are conditioned to the expression of biomarkers that require specific tools in routine to measure them. We will detail in this chapter several techniques of anatomopathology, cytogenetics and molecular biology necessary for the detection of biomarkers in lung cancers, and their applications in thoracic oncology in 2018.
肺癌是法国癌症死亡的主要原因，每年约有30000人死亡。绝大多数（90%）与烟草有关。预后严峻，但随着靶向治疗的发展，随后免疫治疗的出现，治疗取得了巨大进展。这些药物取决于生物标志物的表达，而这需要在常规检测中使用特定工具来进行测量。在本章中，我们将详细介绍几种用于检测肺癌生物标志物的解剖病理学、细胞遗传学和分子生物学技术，以及它们在2018年胸部肿瘤学中的应用。
